All vaccines 💉 produced under this initiative will be available to all countries in Latin America and the Caribbean through PAHO’s Revolving Fund benefiting the entire Region 🌎
Both institutions have a long track record of vaccine manufacturing 📦 and will build on this legacy to protect people across the region 🌎 from the threat of COVID and from future health risks.
This is a strategic initiative because mRNA technology can also be used to develop other virus vaccines 💉 for relevant public health problems in our Region such as Zika, Dengue fever and other 🦠
…– to receive technical support from PAHO and WHO to accelerate the development and production of mRNA vaccines 💉, the same technological platform used by Pfizer and Moderna, in Latin America and the Caribbean.
… – the public producer Bio-Manguinhos Institute of Technology on Immunobiologicals at the Oswaldo Cruz Foundation in Brazil, and the private company Sinergium Biotech in Argentina…
After reviewing 🔍 more than 30 proposals 📄, an external and independent committee of experts selected two projects…
As we address these immediate gaps, PAHO is also working to expand our region’s manufacturing capacity to build a more sustainable and dependable supply of vaccines 💉 and medical technologies.
We have reached an agreement with Sinovac & have begun accepting orders that will be ready for delivery this year, & we are expecting to sign new agreements in the coming days to buy 💉 that have Emergency Use Listing approval from other suppliers for 2021 & 2022
Our Revolving Fund is in advanced discussions with vaccine manufacturers to purchase additional COVID vaccines 💉 on behalf of our Member States, to complement bilateral deals, donations 📦, and doses they are receiving via the COVAX mechanism.
We must use all possible strategies to access more doses 💉
